Effects of Rosuvastatin calcium and nicotinic acid in the treatment of ACS patients with high plasma lipoprotein(α)

XING Qing-mei; LI Li; WANG Yuan-yuan

doi:10.3969/j.issn.1672-5301.2017.09.019

Abstract：Objective To investigate effects of Rosuvastatin calcium and nicotinic acid in the treatment of ACS patients with high plasma lipoprotein(α) and the changes of endothelial function.Methods From June 2015 to July 2016,178 ACS patients with high plasma lipoprotein (α) who were treated in our hospital were randomly divided into observation group(n=80) and control group(n=98).The observation group was given the treatment of Rosuvastatin calcium and nicotinic acid,the control group was treated with Rosuvastatin calcium.The levels of blood lipids,adiponectin (APN),endothelial progenitor Cells (EPCs) and flow-mediated dilation (FMD) were observed in two groups before and after treatment.Results TC,TG,LDL-C and Lp (α) in the two groups after treatment 3 months were lower than before treatment,while HDL-C was higher than before treatment (P＜0.05).The TG,LDL-C and Lp (α) in the observation group at 3 months after treatment were significantly lower than those in the control group,while HDL-C was significantly higher than that in the control group (P＜0.05).APN,EPCs and FMD in the two groups after treatment 3 months were higher than before treatment(P＜0.05).The observation group after treatment 3 months APN,EPCs and FMD were (210.40±40.27)μg/L,(0.050±0.002)％ and (6.01±0.70)％,significantly higher than the control group,the difference was statistically significant(P＜0.05).No serious adverse reactions occurred in the two groups.Conclusion The Rosuvastatin calcium and nicotinic acid can reduce the level of lipoprotein (α) and improve the vascular endothelial function in patients with ACS with high plasma lipoprotein(α).